AHFS October 2024 Update

This update contains 5 new monographs and 37 revised monographs.

New monographs: Afamitresgene Autoleucel; Crovalimab-akkz; Donanemab-azbt; Ensifentrine; Sofpironium Bromide.

Revised monographs: Armodafinil; Bimekizumab-bkzx; Cipaglucosidase alfa-atga; Cladribine (Immunomodulatory Agent); Clevidipine Butyrate; Desvenlafaxine, Desvenlafaxine Succinate; Dolutegravir Sodium; Dolutegravir Sodium and Rilpivirine Hydrochloride; Dornase Alfa; Efbemalenograstim alfa-vuxw; Emtricitabine and Tenofovir Disoproxil Fumarate; fentaNYL, fentaNYL Citrate; Fingolimod Hydrochloride; Fostemsavir Tromethamine; Heparin Sodium; Iptacopan Hydrochloride; Levomilnacipran Hydrochloride; Monomethyl Fumarate; Natalizumab; Nirogacestat Hydrobromide; Nirsevimab-alip; Oteseconazole; Peginterferon Alfa (Antiviral); Pemigatinib; Pitavastatin Calcium, Pitavastatin Magnesium; Ponesimod; Pralsetinib; Respiratory Syncytial Virus Vaccine; Respiratory Syncytial Virus Vaccine (mRNA); Respiratory Syncytial Virus Vaccine, Adjuvanted; Reteplase; Retifanlimab; Rocuronium Bromide; Tacrolimus (Atopic Dermatitis); Tenecteplase; Vasopressin; Vecuronium Bromide.